<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[진메디신 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=34399></link><description><![CDATA[진메디신 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Fri, 15 May 2026 18:37:51 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/01/12_3554238800_20200121133000_5112034228.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[GeneMedicine Appoints MIT Professor Robert S. Langer, Sc.D to Its Scientific Advisory Board]]></title><link>https://www.newswire.co.kr/newsRead.php?no=900310</link><description><![CDATA[SEOUL--(Korea Newswire)--GeneMedicine Co., Ltd., a leader in the field of oncolytic adenovirus platform for the treatment of intractable cancers, announced that the company has appointed Robert S. Langer, Sc.D., the David H. Koch Institute Professor at MIT to its Scientific Advisory Board.  Dr. Langer is a world-renowned scientist and entrepreneur and is widely regarded...]]></description><pubDate>Tue, 21 Jan 2020 13:34:24 +0900</pubDate></item></channel></rss>